Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report.

Leonard KapsChristian LabenzDaniel GrimmAndreas SchwartingPeter R GalleOliver Schreiner

Published in: Clinical case reports (2020)

The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID-19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.

Keyphrases

case report
coronavirus disease
sars cov
intensive care unit
acute respiratory distress syndrome
acute kidney injury
early onset
mechanical ventilation
extracorporeal membrane oxygenation
septic shock
combination therapy
replacement therapy